Spots Global Cancer Trial Database for Study of Cryoablation and Nirogacestat for Desmoid Tumor

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of Cryoablation and Nirogacestat for Desmoid Tumor

Official Title: Phase II Study of Cryoablation and Nirogacestat for Desmoid Tumor

Study ID: NCT05949099

Conditions

Desmoid Tumor

Interventions

Nirogacestat

Cryoablation

Study Description

Brief Summary: The primary purpose of this protocol is Systemic therapy with oral study agent, nirogacestat, followed by a single cryoablation procedure.

Detailed Description: The primary purpose of this protocol is treatment. Systemic therapy with oral study agent, nirogacestat, will be given for 3 cycles (1 cycle = 28 days) followed by a single cryoablation procedure between Cycles 3 and 4, and then continued nirogacestat for Cycles 4 through 26. Treatment with nirogacestat may continue via this study for up to 24 months (26 cycles of treatment), unless there is progression of disease, intolerance, subject withdraws their consent, start of a new anticancer therapy, or until Subject Study Completion or Termination occurs.